23rd Mar 2020 14:35
(Alliance News) - Indivior PLC on Monday said a long-term study suggests buprenorphine treatment can have a positive effect in those with opioid use disorders.
Indivior is facing significant action over opioids. It is currently facing a civil investigation in the US over the marketing and promotion of Suboxone, a treatment for opioid addiction, and its interaction with a non-profit third-party.
Last Apri, it also was indicted on 28 felony counts related to fraud. It could face USD3 billion of fines.
On Monday, Indivior said a two-year "RECOVER" study suggested treatment with buprenorphine could have a positive outcome in those recovering from opioid addiction. The study examined individuals with moderate to severe addiction.
Buprenorphine, also known as Sublocade, is injected under the skin.
"These latest RECOVER findings build on the volume of data released recently about current trends in opioid use disorder treatment and the opioid epidemic in America, and provide further support for the benefits of long-term treatment with Sublocade including counselling for people struggling with this disease," said Christian Heidbreder, chief scientific officer at Indivior.
"Our investment in the RECOVER study reflects our commitment to understanding patient progress in the short, medium, and long-term to gain additional insights about how to best use medications to support recovery efforts."
Shares were 5.3% lower on Monday in London at 46.69 pence each. In the summer of 2018, they fetched nearly 500p.
By George Collard; [email protected]
Copyright 2020 Alliance News Limited. All Rights Reserved.
Related Shares:
Indivior